| HOME >> BIOLOGY >> TECHNOLOGY |
Other current assets 4,037 6,082
Plant and equipment, net of accumulated
depreciation and amortization 337 19,849
Debt issuance costs 8,248 5,569
Other assets, net of accumulated amortization 13,465 9,633
Total assets $361,489 $224,740
Liabilities and Stockholders' Equity (Deficit)
Current liabilities $28,927 $25,423
Current notes payable 191,265 19,044
Long-term notes payable and other liabilities 350,995 373,517
Total liabilities 571,187 417,984
Paid-in capital and common stock 681,536 677,520
Accumulated other comprehensive loss (500) (1,892)
Accumulated deficit (890,734) (868,872)
Net stockholders' deficit (209,698) (193,244)
Total liabilities and stockholders' deficit $361,489 $224,740
About NPS Pharmaceuticals
NPS develops small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.
Conference Call Information
A conference call will be held today at 5:00 p.m. ET. To participate in
the call, dial (866) 770-7051 with passcode 53288322. International callers
may dial (617) 213-8064 using the same passcode. In addition, live audio of
the conference call will be simultaneously broadcast over the Internet
'/>"/>
| SOURCE NPS Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |